-
Signature
-
/s/ Stephen Feider, Attorney-in-Fact
-
Issuer symbol
-
BBNX
-
Transactions as of
-
02 Dec 2025
-
Net transactions value
-
-$88,304
-
Form type
-
4
-
Filing time
-
16 Mar 2026, 19:55:07 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Hopman Mark |
Chief Commercial Officer |
C/O BETA BIONICS, INC., 11 HUGHES, IRVINE |
/s/ Stephen Feider, Attorney-in-Fact |
16 Mar 2026 |
0002048497 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BBNX |
Common Stock |
Sale |
$25,112 |
-856 |
-0.62% |
$29.34 |
138,277 |
02 Dec 2025 |
Direct |
F1 |
| transaction |
BBNX |
Common Stock |
Sale |
$63,192 |
-2,061 |
-1.5% |
$30.66 |
136,216 |
04 Dec 2025 |
Direct |
F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: